Global Assessment of Quality of Care for Patients With Malignant Melanoma
Source: Dermatology Advisor, November 2023
The overall quality of care index (QCI) scores for patients with malignant melanoma improved globally from 1990 to 2019, although all-age disability-adjusted life years (DALYs) increased in the same period. Women and girls were also reported to have higher QCI scores than men and boys. These study results were published in the Archives of Dermatological Research.
Investigators conducted a systematic analysis to evaluate QCI scores for patients with melanoma at global, regional, and national levels. They sourced data from the Global Burden of Disease (GBD) Study 2019 online Global Health Data Exchange query tool which included data on prevalence, incidence, mortality, years of life lost, years lost due to disability, and DALYs for melanoma-related burden between 1990 and 2019. Principal component analysis (PCA) was used to calculate the QCI scores for patients with melanoma.
The global estimated age-standardized DALYs scores for malignant melanoma were 23.58 (95% uncertainty intervals [UI], 19.62-29.92) in 1990 and 20.81 (95% UI, 15.78-24.33) in 2019. The estimated mortality rate for malignant melanoma decreased from 0.85 (95% UI, 0.72-1.10) in 1990 to 0.79 (95% UI, 0.58-0.89) in 2019. In addition, the overall QCI scores for patients with malignant melanoma improved from 82.81 in 1990 to 91.29 in 2019.